Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prime Medicine, Inc. ( (PRME) ) has issued an announcement.
Prime Medicine, Inc. announced the resignation of Keith Gottesdiener as CEO, effective May 18, 2025, with Allan Reine appointed as the new CEO. The company is undergoing a strategic restructuring to focus on large genetic liver diseases and partnered programs, while also reporting positive initial data from its PM359 trial for Chronic Granulomatous Disease, showing promising safety and efficacy results.
The most recent analyst rating on (PRME) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
Prime Medicine, Inc. faces significant financial hurdles with ongoing losses and dependency on external funding. While recent technical indicators show potential for recovery, the stock remains under pressure. The promising preclinical results offer a positive long-term outlook, but the current valuation and financial performance weigh heavily on the overall score.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Prime Medicine, Inc. is a biotechnology company focused on developing next-generation gene editing therapies using its proprietary Prime Editing platform. The company aims to create one-time curative genetic therapies that precisely edit genes to correct mutations, with a focus on liver, lung, immunology, and oncology.
Average Trading Volume: 1,517,325
Technical Sentiment Signal: Sell
Current Market Cap: $208.8M
Find detailed analytics on PRME stock on TipRanks’ Stock Analysis page.